Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Amoxicillin + gentamicin + metronidazole is a combination antibiotic regimen consisting of three generic antimicrobial agents used together to treat uncomplicated acute appendicitis. Amoxicillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, targeting gram-positive bacteria. Gentamicin is an aminoglycoside that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, targeting gram-negative bacteria. Metronidazole is a nitroimidazole that disrupts bacterial DNA, targeting anaerobic bacteria. This triple-therapy protocol provides broad-spectrum coverage against the polymicrobial flora typically implicated in appendicitis. It has been evaluated in Phase 3 clinical trials, such as those sponsored by the University of Queensland, as a non-surgical alternative to laparoscopic appendicectomy in adults with radiologically confirmed uncomplicated disease.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on amoxicillin + gentamicin + metronidazole.